Georgia Clinical Trials Report — April 2026

For Georgians considering participation in clinical research, April 2026 presents a critical window for action, particularly with numerous studies nearing their enrollment deadlines. Across the state, 152 clinical trials are scheduled to close within the next 90 days. This urgency extends to healthy volunteers, as 19 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also have limited time to join ongoing research. Trials focused on heart health, specific cancers, and infectious diseases are among those with impending deadlines for enrollment. Conditions with trials closing soon include:

• Heart failure
• Sickle cell disease
• Gastric cancer
• Advanced breast cancer
• Stage IV lung cancer
• Interstitial cystitis
• HIV-1 infection
• Long COVID
• COVID-19
• Breast cancer

New Research Opportunities Emerge Across Georgia

This month brings 14 new clinical trials to Georgia, offering fresh avenues for participation. While this is a decrease from the 24 new trials that opened in March, the new studies cover a diverse range of health areas and include significant contributions from both academic institutions and major pharmaceutical companies.

A notable aspect of this month's new openings is the opportunity for healthy volunteers. 9 of the 14 new trials are accepting participants without specific health conditions, adding to the 182 total healthy volunteer trials currently recruiting statewide. This provides ample opportunity for individuals simply looking to contribute to medical science.

New trials are addressing a variety of conditions, from common health concerns to more specialized areas. This month's new studies are targeting:

• Acute myeloid leukemia
• Adult obesity
• Alcohol misuse
• Bystander intervention
• Cervical cancer
• Cervical precancer
• Chronic myeloid leukemia (refractory/relapsed)
• Compliance behaviors
• COVID-19

The types of interventions being studied are varied, with drug trials leading the way, accounting for 7 of the new trials. Behavioral interventions represent 6 new trials, and one new biological study has also opened.

Spotlight on Groundbreaking Phase 2 and 3 Trials

Several high-profile new trials have launched in Georgia this month, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and interventions, addressing a range of health challenges.

• RTI International is sponsoring the "Safer Drinking Spaces Study," NCT07527988. This large behavioral study aims to enroll 3,180 participants to evaluate active bystander training for staff in alcohol-serving establishments. The goal is to improve norms around violence and create safer environments by teaching intervention techniques.
• Incyte Corporation is initiating NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants to assess the efficacy and safety of this combination therapy.
• Caliway Biopharmaceuticals Co., Ltd. is launching NCT07526974, a Phase 3 study titled "SUPREME-02." This randomized, double-blinded, placebo-controlled trial will evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat, enrolling 320 participants.
• Eccogene is sponsoring the "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial," NCT07505303. This Phase 2 study, involving 160 participants, will assess the effect of oral ECC4703 on body weight reduction and, in a sub-study, on liver fat content.
• Eli Lilly and Company is conducting NCT07533019, a Phase 2 study of LY4005130 in adult participants with non-segmental vitiligo. This trial aims to enroll 60 participants to evaluate the tolerability and side effects of the investigational drug administered intravenously.

Geographic Reach and Participant Eligibility

Georgia's research landscape remains broad, with 1,967 clinical trials currently recruiting across 99 cities and 1,321 research sites statewide. This month's new trials show a clear concentration in metropolitan areas, with Atlanta leading the way with 9 new studies. Other cities seeing new trial openings include:

• Decatur (2 new trials)
• Alpharetta (1 new trial)
• Athens (1 new trial)
• Augusta (1 new trial)
• Sandy Springs (1 new trial)

While new trial openings are concentrated, the overall research opportunities are accessible across a wide geographic spread, ensuring that many Georgians can find studies close to home.

Participation in clinical trials is open to a diverse range of individuals. Of the 14 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is open to children, and 1 study is specifically designed for female participants.

Academic institutions continue to play a vital role in Georgia's research ecosystem, with Emory University and Georgia State University sponsoring new trials this month. Industry sponsors, including Eli Lilly and Company, Incyte Corporation, Eccogene, and RTI International, are also driving significant research efforts, accounting for a substantial portion of the new studies.

As we move through April, the focus will be on the ongoing enrollment in these significant Phase 2 and 3 trials, alongside the urgent need to fill spots in studies closing soon. Georgians are encouraged to explore these diverse opportunities and contribute to the future of medicine.